Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-108M | $-109M | $-94M | -44.1% | 17.3% | 22.1% |
| 2024 | $8M | $-88M | $-89M | $-82M | -124.8% | -46.1% | -20.0% |
| 2023 | $15M | $-105M | $-112M | $-80M | -148.9% | 517.5% | -32.8% |
| 2022 | $3M | $-161M | $-166M | $-113M | -17493.6% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 9.77 |
| Operating Revenue | 9.77 |
| Operating Expense | 120.27 |
| Research And Development | 86.40 |
| Selling General And Administration | 33.87 |
| Total Expenses | 120.27 |
| Operating Income | -110.50 |
| Total Operating Income As Reported | -110.50 |
| EBITDA | -107.79 |
| Normalized EBITDA | -106.59 |
| EBIT | -108.93 |
| Interest Income | 9.22 |
| Interest Expense | 0.06 |
| Net Interest Income | 9.16 |
| Other Non Operating Income Expenses | -6.46 |
| Other Income Expense | -7.66 |
| Interest Income Non Operating | 9.22 |
| Interest Expense Non Operating | 0.06 |
| Net Non Operating Interest Income Expense | 9.16 |
| Pretax Income | -109 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -109 |
| Net Income From Continuing And Discontinued Operation | -109 |
| Net Income From Continuing Operation Net Minority Interest | -109 |
| Net Income | -109 |
| Net Income Common Stockholders | -109 |
| Net Income Including Noncontrolling Interests | -109 |
| Normalized Income | -107.80 |
| Diluted NI Availto Com Stockholders | -109 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 1.14 |
| Total Unusual Items | -1.20 |
| Total Unusual Items Excluding Goodwill | -1.20 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Impairment Of Capital Assets | 0 |
| Gain On Sale Of Security | -1.20 |
| General And Administrative Expense | 33.87 |
| Other Gand A | 33.87 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc.this co. | TSHA | $1.7B | -15.53 | 6.85 | -44.1% | -13.39 |
| UFP Technologies, Inc. | UFPT | $1.7B | 25.43 | 4.10 | 16.1% | 16.79 |
| Biohaven Ltd. | BHVN | $1.7B | -2.32 | 32.96 | -1418.8% | -2.41 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | -4.15 | 1.44 | -34.6% | -3.56 |
| Sionna Therapeutics, Inc. | SION |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.7B |
| -22.66 |
| 5.56 |
| -24.5% |
| -18.75 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| Addus HomeCare Corporation | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Peer Median | - | -3.24 | 4.76 | -29.6% | 0.51 | |